WuXi Biologics to invest €325m to build biomanufacturing facility in Ireland. Credit: PRNewsfoto/WuXi Biologics.

China-based WuXi Biologics is set to construct a biologics drug substance manufacturing facility worth about €325m in Dundalk, Ireland.

The construction of the company’s first site outside of China is supported by the Irish Government through the Industrial Development Authority.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

WuXi offers biologics platforms for the discovery, development and manufacture of biologics from concept to commercial manufacturing.

The building will feature several single-use bioreactors for commercial biomanufacturing and is compatible with a next generation manufacturing technology called continuous bioprocessing.

WuXi Biologics CEO Dr Chris Chen said: “We are all excited to initiate our first global site to enable local companies and expedite biologics development in Europe.

“We will work with all local partners to build this state-of-art next generation biomanufacturing facility as a showcase to the global biotech community.”

“In addition, this is the start and a critical part of our global biomanufacturing network to ensure that biologics are manufactured at the highest quality and with a robust supply chain to benefit patients worldwide.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are committed to Ireland and will work with all local partners to build this state-of-the-art next-generation biomanufacturing facility as a showcase to the global biotech community.”

A 48,000l fed-batch and 6,000l perfusion bioreactor capacity will be installed, representing the world’s largest facility using single-use bioreactors.

Ireland Minister for Business, Enterprise and Innovation Heather Humphreys said: “This huge €325m investment is a great vote of confidence in Ireland and reinforces our image as a global centre of excellence in Biologics.

“This investment will result in the creation of over 400 highly skilled jobs over five years, as well as approximately 700 construction jobs.”